Encouraging antitumor activity was noted among patients with melanoma in the early cohorts, while enhanced effects were observed in later cohorts in patients with melanoma refractory to anti-cell death protein 1 (PD-1) and anti-programmed death-ligand 1 (PD-L1) treatments, evidenced by an overall response rate of 33.3% (n= 33) [59]. The gene discussed is CD274; the disease is melanoma.